A randomized, double-blind, placebo-controlled clinical study on the treatment of community-acquired with feiyan qinghua decoction

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063115

Enrollment

Unknown

Registered

2022-08-31

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

community-acquired pneumonia (CAP)

Interventions

Experimental group:Feiyan Qinghua decoction

Control group:placebo

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Consistent with CAP Western diagnostic standards; 2. Meeting TCM diagnostic criteria of phlegm-heat obstructing lung syndrome; 3. Aged 18-85 years; 4. Patients who have not used antibiotics within 72h after the onset of the disease; 5. Patients participate voluntarily and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with complicated immune system diseases or long-term use of immunosuppressants; 2. Complicated with severe cardiovascular, liver, kidney and hematological diseases; 3. Mental patients; 4. Allergic to study drugs; 5. Poor compliance, unable to cooperate with treatment.

Design outcomes

Primary

Measure	Time frame
Total score of TCM symptoms, score of main symptoms and secondary symptoms;	—

Secondary

Measure	Time frame
Blood routine;Cellular immunity and humoral immunity;Cytokines;Chest computed tomography;Nine respiratory viruses;	—

Countries

China

Contacts

Public ContactXu Guihua

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

noan9602@163.com+86 13585636986

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026